15th Nov 2019 07:49
(Alliance News) - Pharmaceutical firm AstraZeneca PLC has received European Commission approval for a type-2 diabetes treatment, it said on Friday.
The EC has given the thumbs up to Qtrilmet, which is made up of metformin hydrochloride, saxagliptin, and dapagliflozin. Qtrilmet is a tablet taken once a day to improve glycaemic control in adults with the condition.
The approval is based on data from five phase three trials, AstraZeneca said, which delivered positive efficacy and safety results.
Qtrilmet received approval from regulators in the US in May this year.
By George Collard; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca